How Catequentinib Interacts with Other Drugs in Healthy Volunteers
Treatments studied
This study tests how a new anti-cancer drug called catequentinib (AL3818) interacts with other medicines in healthy people. It helps researchers understand how the drug is processed in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are generally healthy with no major medical problems.
- You have not taken any prescription or over-the-counter medicines, vitamins, or herbs in the last 2 weeks.
- You do not smoke more than 5 cigarettes per day and do not drink alcohol heavily.
- You are willing to avoid certain foods and drinks (like grapefruit, caffeine, and alcohol) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug called TQB3616 interacts with other medicines. It is for healthy volunteers aged 18 to 45 to help understand how the drug is processed in the body.
This study looks at how two common medicines, itraconazole and rifampin, change the levels of a new drug called Rocbrutinib in healthy volunteers. The results will help doctors understand how to use Rocbrutinib safely in future patients.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
This trial studies how the drug clifutinib is processed by the body when taken with other medicines (itraconazole, fluconazole, or efavirenz). Healthy volunteers will receive a single dose of clifutinib plus one of these other drugs to see how they affect each other.
Hear when a new Healthy Volunteer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.